HCW BIOLOGICS INC. news, videos and press releases
For more news please use our advanced search feature.
HCW BIOLOGICS INC. - More news...
HCW BIOLOGICS INC. - More news...
- HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements
- HCW Biologics Granted FDA Clearance to Evaluate One of the Company’s Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial
- HCW Biologics’ Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025
- HCW Biologics Inc. Received NASDAQ Staff Determination Letter
- HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules
- HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate
- HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights
- HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction
- HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights
- HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights
- HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights
- HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights
- Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting
- Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting
- HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023
- HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
- HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders
- HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights
- HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan
- HCW Biologics Poster Presentation at AACR Annual Meeting 2023
- A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases
- HCW Biologics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
- HCW Biologics Enters CRADA with National Cancer Institute
- HCW Biologics is Granted Second Fundamental Patent: U.S. Patent for Multi-Chain Chimeric Polypeptide Created with TOBI™ Platform
- Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation From the Phase 1 Clinical Trial to Evaluate HCW9218 in Solid Tumors At the SITC 37th Annual Meeting
- HCW Biologics Reports Third Quarter 2022 Financial Results And Recent Business Highlights
- HCW Biologics Reports Second Quarter 2022 Financial Results And Recent Business Highlights
- U.S. Patent Issued to HCW Biologics for Foundational Platform Technology
- HCW Biologics to Participate in H.C. Wainwright Annual Global Life Sciences Conference May 23 – 25, 2022
- HCW Biologics Reports First Quarter 2022 Financial Results and Recent Business Highlights
